Costs of treatment after renal transplantation: is it worth to pay more?

Document Type: Research article

Authors

1 shahid Beheshti School of Pharmacy

2 School of Pharmacy, Shahid Beheshti University of Medical Sciences

3 School of pharmacy, Shahid Beheshti school of pharmacy

4 school of pharmacy, Shahid Beheshti School of pharmacy

5 Tarbiat Modares University

6 School of Pharmacy, Tehran University of Medical Sciences

7 Urinary and Nephrology research center, Shahid Beheshti University of Medical Sciences

Abstract

Objectives: The present study aimed to provide an estimation of the current financial burden of renal transplantation therapy for insurance organisations.
Methods: An Excel-based model was developed to determine the treatment costs of current clinical practice in renal transplantation therapy (RTT). Inputs were derived from Ministry of Health and insurance organizations` database, hospital and pharmacy records, clinical trials and available literature. A one-way sensitivity analysis and Monte-Carlo simulation were performed to illustrate total cost changes made by cost components and to test the reliability of model probabilities respectively.
Results: According to the model, 2200 patients received RTT in the study year which resulted in the first year total treatment cost of almost $14,000,000. These costs corresponded to annual total cost per patient of almost $6500 for the payers.
Conclusion: According to the results of the study, treatment cost per patient in RTT is almost $6500 for the payers in Iran. Although RTT is almost fully reimbursed by government in Iran, an improvement in insurance decision making especially regarding new effective immunosuppressive drugs is quite necessary for controlling growing trends of OOP expenditures in these patients. The present study aimed to improve efficiency in budget allocation by providing insurance decision makers with an estimation of financial impact of current clinical practice in RTT, making it possible for them to compare current financial burden of the disease with the future cost burden of including newly submitted drugs to their formulary in RTT and also provided practical policy making recommendations in the end.

Keywords

Main Subjects